EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSLDG00000020944
Gene Symbol: HTR2A
4 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSSLDG00000002688
Gene Symbol: LOC111667109
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSSLDG00000011404
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSLDG00000002895
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSLDG00000002836
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSLDG00000007212
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSLDG00000022034
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSSLDG00000008719
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSSLDG00000004406
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L11-Like

Ensembl ID : ENSSLDG00000008766
Gene Symbol: LOC111660169
3 Cross references
212 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSSLDG00000019425
Gene Symbol: LOC111657085
3 Cross references
328 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSSLDG00000016849
Gene Symbol: LOC111658871
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).